Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPCOG-II: HCV Eradication and Neurocognitive Function
NCT02292966Phase 4Withdrawn
- Sponsor
- The Kirby Institute
- Start
- Jul 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of daclatasvir, asunaprevir, beclabuvir in hepatitis C (HCV), sponsored by The Kirby Institute. Planned start Jul 2015; status: withdrawn.
02
Drugs
daclatasvirasunaprevirbeclabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02292966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292966.